LEI: 549300Q7EXQQH6KF7Z84
18 April 2024
RTW Biotech Opportunities Ltd
(the "Company")
Notice of Annual General Meeting
RTW Biotech Opportunities Ltd announces that its Annual General Meeting ("AGM") will be held at 1st Floor Royal Chambers, St Julian's Avenue St Peter Port, Guernsey on 16 May 2024 at 2pm BST. The Notice of AGM was dispatched to all shareholders on 17 April 2024.
A copy of the Notice of AGM has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism The Notice of AGM may also be viewed on the Company's website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
The Annual Report and Audited Financial Statements for the year ended 31 December 2023 (the "Annual Report") is also available on the Company's website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
You will not have received a hard copy proxy form for the AGM in the post. You can instead submit your proxy vote electronically by accessing the shareholder portal at www.signalshares.com, logging in and selecting the 'Vote Online Now' link. Full details of how to vote are set out in the Notes to the Notice of Meeting. Please submit your proxy vote so as to reach the Company's registrar as soon as possible and in any event no later than 2pm BST on 14 May 2024 or, if you are a CREST member, by using the service provided by Euroclear. Shares held on your behalf by a broker or nominee must be voted by the broker, per your instructions, and cannot be voted at www.signalshares.com. The completion of the form of proxy will not preclude a member from attending and voting in person at the meeting if it is so allowed.
If any shareholder has questions related to the business of the AGM, please submit your queries to biotechopportunities@rtwfunds.com by 2pm BST on 14 May 2024. We will endeavour to answer every shareholder question and responses will be posted on the Company's website after the AGM.
For Further Information
| RTW Investments, LP | +44 20 7959 6361 |
| Woody Stileman, Managing Director, Business Development Krisha McCune, Director, Investor Relations | |
|
|
|
|
Buchanan (PR & Communications Adviser) |
+44 20 7466 5107 |
| Charles Ryland |
|
| Henry Wilson |
|
| George Beale |
|
|
|
|
| Deutsche Numis (Joint Corporate Broker) | +44 20 7260 1000 |
| Freddie Barnfield |
|
| Nathan Brown |
|
| Euan Brown |
|
| |
|
| BofA Securities (Joint Corporate Broker) | +44 20 7628 1000 |
| Edward Peel |
|
| Alex Penney |
|
|
Cadarn Capital (Distribution & IR Partner) |
+44 73 6888 3211 |
| David Harris |
|
|
Elysium Fund Management Limited Joanna Duquemin Nicolle, Chief Executive Officer Sadie Morrison, Managing Director
|
+44 14 8181 0100 |
| Morgan Stanley Fund Services USA LLC | +1 914 225 8885 |
About Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.